NEW YORK and LONDON, November 5, 2015 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Akari Therapeutics Closes $75 Million Private Placement
NEW YORK and LONDON, September 21, 2015 AAkari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX), an emerging growth, …
[Read more...] about Akari Therapeutics Closes $75 Million Private Placement
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc
NEW YORK and LONDON, September 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following …
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement
NEW YORK and LONDON, August 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered …
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition
NEW YORK and LONDON, July 13, 2015 Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a …
